Sanofi (EPA:SAN) received a €81.00 ($94.19) target price from investment analysts at JPMorgan Chase & Co. in a report issued on Monday, June 3rd, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 6.69% from the stock’s current price.
A number of other equities research analysts also recently commented on the company. Goldman Sachs Group set a €77.00 ($89.53) target price on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, March 28th. Deutsche Bank set a €93.00 ($108.14) target price on Sanofi and gave the company a “buy” rating in a research note on Friday, February 8th. Credit Suisse Group set a €82.00 ($95.35) target price on Sanofi and gave the company a “buy” rating in a research note on Friday, February 8th. Jefferies Financial Group set a €90.00 ($104.65) target price on Sanofi and gave the company a “buy” rating in a research note on Thursday, February 7th. Finally, UBS Group set a €82.00 ($95.35) target price on Sanofi and gave the company a “neutral” rating in a research note on Thursday, February 7th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Buy” and a consensus price target of €85.67 ($99.61).
EPA:SAN traded down €1.13 ($1.31) during mid-day trading on Monday, hitting €75.92 ($88.28). 2,837,801 shares of the company traded hands, compared to its average volume of 3,050,000. The company has a fifty day moving average of €75.25. Sanofi has a one year low of €63.09 ($73.36) and a one year high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.